COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.
Sponsor: Bristol-Myers Squibb
This PHASE1/PHASE2 trial investigates Endometrial Neoplasms and Head and Neck Cancer and is currently completed. Bristol-Myers Squibb leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Compugen Ltd
For direct contact, visit the study record on ClinicalTrials.gov .